Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure

Harvey S. Chen, Dong Jin Joo, Mohammed Shaheen, Yi Li, Yujia Wang, Jian Yang, Clara T. Nicolas, Kelly Predmore, Bruce Amiot, Gregory Michalak, Taofic Mounajjed, Jeff Fidler, Walter K. Kremers, Scott L. Nyberg

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio-artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild-type large white swine (20 kg-30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24-48 hours after hepatectomy: Group1—standard medical therapy (SMT, n = 6); Group2—SMT plus bio-artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3—SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200-g group survived to 90 hours (P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200-g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200-g group compared with the SMT (P < 0.01) and 0-g (P < 0.01) groups. Ki-67 staining showed increased positive staining at 48 hours following hepatectomy (P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.

Original languageEnglish (US)
Pages (from-to)329-342
Number of pages14
JournalHepatology
Volume69
Issue number1
DOIs
StatePublished - Jan 2019

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure'. Together they form a unique fingerprint.

  • Cite this

    Chen, H. S., Joo, D. J., Shaheen, M., Li, Y., Wang, Y., Yang, J., Nicolas, C. T., Predmore, K., Amiot, B., Michalak, G., Mounajjed, T., Fidler, J., Kremers, W. K., & Nyberg, S. L. (2019). Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure. Hepatology, 69(1), 329-342. https://doi.org/10.1002/hep.30184